Success Metrics

Completion Rate
0%(0/2)
Active Trials
0(0%)
Terminated
2(67%)

Phase Distribution

Ph phase_1
2
67%

Phase Distribution

2

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Phase 1Safety & dosage
2(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 2 finished

Non-Completion Rate

100.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Terminated(2)
Other(1)

Detailed Status

Terminated2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
0.0%
Most Advanced
Phase 1

Trials by Phase

Phase 12 (100.0%)

Trials by Status

terminated267%
unknown133%

Recent Activity

0 active trials
Showing 3 of 3
terminatedphase_1

A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia

NCT03225716
terminatedphase_1

Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors

NCT02472977
unknown

Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma

NCT02666209

Clinical Trials (3)

Showing 3 of 3 trials
NCT03225716Phase 1

A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia

Terminated
NCT02472977Phase 1

Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors

Terminated
NCT02666209

Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma

Unknown

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3